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A B S T R A C T
We report a 13-year-old boy hospitalized for the first time at the age of 17 months with clinical and laboratory signs of
chronic kidney disease (CKD) and renal osteodystrophy caused by severe obstructive uropathy of the single kidney. Pre-
vention and treatment of renal osteodystrophy has been target for aggressive therapy and the great challenge for pediat-
ric nephrologists. The outcome of the therapy of renal osteodystrophy is influenced by medical and non – medical factors.
It was concluded that the place of living (in our example a small village distant from primary care physicians, far from
the social care professionals and far from the hospital), inferior social and economical status with inadequate nutrition
present negative factors that contributed to the outcome and development of CKD and its complications as is renal
osteodystrohy. The coordination of medical and non – medical professionals is necessary on the primary and secondary
level to achieve positive results of therapy in patients with CKD.
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Introduction
In childhood, chronic kidney disease (CKD) causes
disordered regulation of mineral and bone metabolism,
with subsequent alterations in bone strength and growth
failure. Renal osteodystrophy is the specific term used to
describe the bone pathology that is manifested by either
one or a combination of abnormalities of calcium, phos-
phorus, parathyroid hormone (PTH), or vitamin D meta-
bolism1. Beside biomarkers, prevention and treatment of
renal osteodystrophy depend on abnormalities in bone
turnover, mineralization, and bone growth with bone de-
formities common in infants and other children with
long-standing CKD2. However, the final outcome of the
therapy of renal osteodystrophy is often influenced by
medical and non – medical factors, such as place of living,
culture, economical and social status and family educa-
tion. The coordination of medical and non – medical pro-
fessionals is necessary on the primary and secondary
level to achieve positive results of therapy in patients
with renal osteodystrophy.
Case Report
We present a 13-year-old boy who was hospitalized for
the first time at the age of 17 months with clinical and
laboratory parameters indicative of chronic kidney dis-
ease (CKD) stage 3. He presented with clinical signs of
urosepsis and severe obstructive uropathy of the single
kidney due to pyeloureteral junction stenosis and consec-
utive hydronephrosis grade IV. His previous medical his-
tory was indicative for several febrile episodes and feed-
ing problems since birth, and walking difficulties obser-
ved by his parents just prior to admission. Initial clinical
evaluation showed decreased glomerular filtration rate
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(GFR 30 mL/min/1.73 m2, Schwartz formula), metabolic
acidosis (serum bicarbonate 16 mmol/L) and anemia (Hb
90 g/dl) in addition to poor growth below the third per-
centile and clinical and X-ray signs of overt rickets (swol-
len ankles, genu valgum). Left hand and wrist X-ray
showed bone age corresponding to 6 month old child with
metaphyseal widening typical for rickets. The biochemi-
cal parameters of plasma calcium (2.2 mmol/L), phos-
phate (1.92 mmol/L), alkaline phosphatase (336 U/L,
normal <300 U/L) and intact parathyroid hormone
(PTH 28.2 pmol/L, normal <7.6 pmol/L) were indicative
of vitamin-D-deficient rickets, indicating therapy with
cholecalciferol (2000 units/day/3 months). Following the
initial therapy with antibiotics, correction of metabolic
acidosis, anemia, treatment of rickets and adequate diet,
he stayed in hospital for 3 months, until the indicated
surgical procedure for hydronephrosis was undertaken
(sec. Anderson-Hynes). In the meantime, his clinical con-
dition significantly improved and he could walk without
any difficulties. In addition to improved radiological sig-
ns of rickets, control biomarkers showed normalization
of alkaline phosphatase (143 U/L) but low plasma 1.25-
-(OH) vitamin D3 (21 pmol/L, normal 48–182 pmol/L for
age) indicating renal osteodistrophy. He was discharged
with prescribed therapy including low phosphate diet
(reduction of dairy products) and protein intake of 1.2
g/kg/day, calcium-containing phosphate binders (CaCO3
500 mg/day) and calcitriol (Rocaltrol 0.25 mg/day) plus
cholecalciferol (400 units/day). From that time on, how-
ever, living in a mountain village far from the hospital
and far from his primary care physician, he was fol-
lowed-up infrequently, no more than 2–3 times a year, of-
ten without any control for several months. Despite
healed rickets and initial catch-up growth, his renal
function progressively deteriorated and within next 5
years CKD reached stage 4. As he started school, he was
even more irregularly seen by nephrologists, the compli-
ance with prescribed diet and anticipated therapy was
poor and often interrupted for prolonged periods. By the
age of 10 years, after he was without any control for al-
most 2 years, he eventually presented with severe com-
plications of renal osteodystrophy, i.e. deformed both legs
(genu valgum) with crossed knees (intermaleolar dis-
tance of 20 cm) causing pain and severe walking difficul-
ties. At that time, beside retarded growth, left hand and
wrist X-ray corresponded to 6 year-old boy (Figure 1).
Radiological signs of renal bone disease of hand, knees
and predominantly lower extremities (periostal resorp-
tion zones and metaphyseal changes) were in correlation
with elevated PTH (max. 274 pmol/L), high calcium
phosphorus product (5.4 mmol/L) and decreased 1,25-
-(OH) vitamin D3 (28 pmol/L) and 25-(OH) vitamin D3
(24 nmol/L). Osteodensitometry (DXA) of lumbar spine
(BMD 0.644 g/cm2, T score –4.1, Z-score –0.4) and left hip
(T score –2.3) confirmed law bone mineral density indi-
cating osteoporosis. Bone biopsy was not undertaken,
but according to histological analysis of intraoperative
bone resection, a few months later, clinically presumed
diagnosis of osteomalacia, was confirmed. Consultant or-
thopedic surgeon, due to severe skeletal deformities indi-
cated surgical correction of bone deformities. Prior to the
first scheduled operation, prescribed therapy for renal
osteodistrophy was intensified (CaCO3 2500 mg/day, cal-
citriol 0.75 mg/day, cholecalciferol 1000 units/day oraly)
with improvement of serum calcium, phosphorus and
PTH. In the meantime, by the age of 12 years, just before
the surgical correction was undertaken, our patient rea-
ched end stage renal disease and started haemodialysis 3
times a week. Histological analysis of resected bone con-
firmed pure osteomalacia with accumulation of osteoid
without mineralization within thin bone trabecule ex-
cluding osteitis fibrosa cystica and adynamic renal osteo-
dystrophy. Final result of both orthopedic corrections
was rather satisfactory. We retrospectively analyzed our
patient’s biomarkers of renal bone disease through the
whole period of observation including plasma calcium,
phosphorus and the level of PTH. The aim of this retro-
spective study was to evaluate if such severe complica-
tions of renal osteodystrophy causing deformities of lo-
wer extremities could have been prevented. As shown,
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Fig. 1. Patient’s age and delayed bone age based on radiological
analysis (left hand) during follow-up in the patient with chronic
kidney disease.
Fig. 2. The plasma values of calcium, phosphorus and parathy-
roid hormone during follow-up period of the patient with chronic
kidney disease. Period between 2002 and 2004 without the
control show the aggravations of laboratory parameters).
main aggravations of clinical and biomarkers of renal
bone disease were in periods when he was without con-
trol, particularly during prolonged stay at home (as be-
tween 2002 and 2004) indicating poor compliance with
prescribed diet and probably without any therapy for re-
nal osteodystrophy (Figure 2). Contrary, during the 6-
-month stay at the hospital while awaiting between the
two operations, taking prescribed medications regularly,
control biomarkers of renal bone disease, including the
level of PTH, calcium, phosphorous and active vitamin D
metabolites, significantly improved. Control osteodensi-
tometry undertaken after second surgical correction and
12-month regular therapy showed improvement (BMD
0.776g/m2, T-2.9, Z-0.1). At that point, with pain reduc-
tion, better ability to walk even with, and afterwards,
without crutches, he was able to return to school and
ready to start evaluation for renal transplantation.
Discussion
The bone growth in childhood is under direct influ-
ence of a variety of hormones and growth factors includ-
ing growth hormone, thyroid hormone, estrogen, testos-
terone, parathyroid hormone, vitamin D and insulin –
like growth factor. A wide range of skeletal abnormalities
are described in patient with CKD, but some of them are
specific and the unique consequence of renal osteody-
strophy on the growing skeleton1–3. According to some
authors both PTH assay (»intact« and »whole« PTH as-
say) seem to provide similar information in regard to
bone turnover in patients with CKD4. The study by
Sheth and Goldstein suggested that management of re-
nal osteodystrophy based on correlation between iPTH
levels and bone biopsy findings should not be extrapo-
lated using the newer 1–84 PTH assay5. The patient pre-
sented here had the proportion of severe bone disease
corresponding to renal osteodystrophy from the time he
presented. Compared to K/DOQI’s (National Kidney Foun-
dation Kidney Disease Outcomes Quality Initiative) clin-
ical signs and symptoms of bone disease in children with
CKD1, this patient had metabolic (hyperphosphathemia,
elevated alkaline phosphatase), hormonal (altered vita-
min D metabolism and elevated PTH), and radiographic
abnormalities (delayed skeletal maturation and skeletal
changes resembling vitamin-D-deficient rickets) at pre-
sentation. Proximal myopathy, extra skeletal calcifica-
tions and ocular disease were not found. Radiographic
studies can diagnose bone complications such as rickets,
skeletal deformities and delayed bone age. Radiological
investigations play an important role in early diagnosis
and therapy of renal bone disease, but are insufficient
without biochemical markers. More sophisticated diag-
nostic methods have been introduced such as computer
tomography (CT), magnetic resonance imaging (MRI)
and bone biopsy, but plain film radiography still repre-
sents most widely used examination6. The bone biopsy
provides definitive evaluation of renal osteodystrophy,
but it is not routinely performed in clinical setting3. The
bone changes in our patient developed over the years
parallel with the progression of the pathological levels of
PTH concentration, mostly because of non-compliant
therapy and irregular control. Bakr in his study detected
that 61.9% of children in predialysis stage of CKD had
osteopenia (measured by bone mineral density of lumbal
spine) that occurs early and irrespective of duration or
severity of CKD7. Osteodensitometry of lumbal spine in
our patient detected osteoporosis in the predialysis pe-
riod, corresponding to osteomalacia diagnosed during or-
thopedics surgery. As it is recommended, an entire panel
of tests including radiological examination, densitometry
tests, biochemical tests and bone biopsy should be per-
formed for the comprehensive evaluation of the skeleton
in patients with CKD.
The National Kidney Foundation has published 13 ev-
idence based clinical practice guidelines (CPGs) to im-
prove the outcome of patients in all stages of CKD, redu-
ce disparities in care and reduce complications associated
with kidney disease. In 2000, CPG was developed for nu-
trition in CKD and in 2003, for bone metabolism that re-
quires dietary phosphorus restriction9. Parathyroid hor-
mone is a better marker than serum phosphorus to start
with this restriction. Dietary phosphate restriction with
high dose phosphates binder in children with CKD plays
a major role in suppression of secondary hyperparathy-
roidism either directly or through sustained elevation of
circulating active D vitamin10. Despite of several clinical
practice guidelines which were formulated by The Na-
tional Kidney Foundation only a small number of pa-
tients achieved K/DOQI targets11. In our patient, despite
the recommendations, the adequate nutrition with re-
duced phosphate intake was not achieved considering the
elevated concentrations of phosphorus and PTH through
the periods when he stayed at home.
The patient lives on the small farm in the mountain
area of our country. His family is occupied with farming
and raising the cattle, heteroanamnestic data suggests
that the main provision was milk and milks’ products.
The other problem considered in our patient was not com-
pliant with prescribed therapy according to the K/DOQI
and European guidelines1,2 during the periods when he
was staying at home. Living in an isolated village with-
out continuous supervision of the primary care physician
and social workers, with law socio-economical status,
were all the additional obstacles to successful outcome of
the therapy.
O. Lenz et al.11 identified the difficulties of successful
care in chronic kidney disease detecting secondary hy-
perparathyroidism as a serious problem, just like in our
patient. Detected the crucial facts for the improvement
of CKD were raising awareness of CKD and K/DOQI
goals among primary care physicians, early referral to a
nephrologists, timely initiation of renal replacement the-
rapy, exploration of socioeconomic barriers and cultural
differences, continuous patient and physicians’ educa-
tion11. Christensen and Ehlers emphasized that future
clinical research should clarify the role of social support
influencing patients’ mortality in end-stage renal di-
sease12. The Patient Advocacy Committee of the Interna-
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tional Federation of Kidney Foundation developed a set
of rights for individuals with end stage renal failure. Pa-
tients possess those rights regardless of where they live
or what may be their economic, social, ethnic or political
status. Among 20 rights there is a right to prevent renal
osteodystrophy13. This right and the right for different
choice of treatment (peritoneal dialysis was suggested to
patient’s mother) could not be accomplished in our pa-
tient due to patients’ economic and social status correlat-
ing with the place of his living.
Secondary hyperparathyroidism aggravated during the
progression of CKD associated with renal osteodystrophy
and extremity deformities requiring osteotomy. It was as-
sociated with frequent hospitalizations but iregular ap-
pointments by nephrologists and most importantly, non-
-compliance with prescribed therapy and the lack of
multidisciplinary approach in primary care (primary ca-
re physicians, social workers, home nursing visits) sup-
port his illness14. It was concluded that socioeconomic
factors and undertaken role of primary care profession-
als (physicians, social workers, school staff and home
nursing staff) had negative influence on the outcome of
renal osteodystrophy complicated by severe bone defor-
mities that requires surgical correction.
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UTJECAJ MEDICINSKIH I NEMEDICINSKIH ^IMBENIKA NA PROGRESIJU RENALNE
OSTEODISTROFIJE
S A @ E T A K
Prezentiran je slu~aj 13-godi{njeg dje~aka koji je hospitaliziran prvi put u dobi od 17 mjeseci s klini~kim i labora-
torijskim znakovima kroni~ne bubre`ne bolesti i renalne osteodistrofije uzrokovane opstruktivnom uropatijom jedinog
bubrega. Prevencija i lije~enje renalne osteodistrofije je cilj agresivne terapije i veliki izazov za pedijatrijske nefrologe.
Ishod terapije renalne osteodistrofije je pod utjecajem medicinskih i ne-medicinskih ~imbenika. Zaklju~eno je da mjesto
stanovanja (u na{em primjeru malo selo udaljeno od primarne zdravstvene skrbi, socijalne skrbi i bolnice), ni`i socijalni
i ekonomski status obitelji te neadekvatna prehrana predstavljaju negativne ~imbenike koji doprinose razvoju kompli-
kacija kroni~ne bubre`ne bolesti kao {to je renalna osteodistrofija. Koordinacija medicinskih i nemedicinskih stru~nja-
ka je neophodna na primarnoj i sekundarnoj razini kako bi se postigli pozitivni rezultati terapije u pacijenata s kro-
ni~nom bubre`nom bole{}u.
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